2023 World Conference on Lung Cancer (Posters)-EP08.04. Predictors and Outcomes of Pneumonitis in Non-Small Cell Lung Cancer Patients treated with Consolidative Durvalumab

EP08.04. Predictors and Outcomes of Pneumonitis in Non-Small Cell Lung Cancer Patients treated with Consolidative Durvalumab - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to identify clinical predictors, outcomes, and healthcare utilization in immune checkpoint inhibitor (ICI) pneumonitis in locally advanced non-small cell lung cancer (LA-NSCLC) patients who received consolidation durvalumab in real-world practice. The authors retrospectively evaluated NSCLC patients who received durvalumab in Alberta, Canada from January 2018 to December 2021 using the Alberta Immunotherapy Database. Pneumonitis cases were identified based on radiographic changes and clinical assessments. The study found that 26% of patients developed any grade of pneumonitis, with 9% experiencing severe pneumonitis. Corticosteroids were administered to 86% of the pneumonitis patients. Additionally, 53% of patients required admission to the hospital, and 13% of deaths were attributed to pneumonitis. Male gender and pre-existing autoimmune conditions were associated with severe pneumonitis, while the percentage of irradiated lung volume 20Gy (V20) was associated with developing any grade pneumonitis. Development of pneumonitis was found to be an independent risk factor for worse overall survival (OS) and time-to-treatment failure (TTF). Kaplan-Meier curve analysis showed a significant difference between pneumonitis and no-pneumonitis subgroups in terms of OS. The study concluded that the incidence of pneumonitis was comparable to prior studies and higher than the PACIFIC trial. The development of pneumonitis negatively impacted survival and TTF. Multiple clinical and radiation therapy-related factors predicted severe ICI pneumonitis, including higher V20, male gender, and autoimmune status. The study highlights the importance of careful patient selection and monitoring when using consolidation durvalumab in real-world LA-NSCLC population.

Asset Subtitle

Chloe Lim

Meta Tag

Speaker Chloe Lim

Topic Local-Regional NSCLC: Toxicities of Multimodality Therapy

Keywords

immune checkpoint inhibitor pneumonitis

locally advanced non-small cell lung cancer

durvalumab

real-world practice

clinical predictors

corticosteroids

hospital admission

male gender

autoimmune conditions

irradiated lung volume 20Gy